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Gene transcription is controlled by transcriptional regulators acting with specific co-regulators to allow gene
activation and repression. Here, we report the identification of the KRAB-containing zinc-finger transcrip-
tional regulator, ZBRK1, as an interaction partner of the SCA2 gene product ataxin-2. Furthermore, we discov-
ered that an elevated ZBRK1 level resulted in increased ataxin-2 levels, whereas interference on
transcriptional and protein levels of ZBRK1 yielded reduced ataxin-2 levels, suggesting that a complex com-
prising ZBRK1 and ataxin-2 regulates SCA2 gene transcription. A bioinformatic analysis utilizing the known
ZBRK1 consensus DNA-binding motif revealed ZBRK1-binding sites in the SCA2 promoter. These predicted
sites were experimentally validated by chromatin-immunoprecipitation experiments along with luciferase-
based promoter analyses corroborating that SCA2 gene transcription is controlled by a ZBRK1/ataxin-2 com-
plex. Finally, we demonstrate that SCA2 gene transcription is significantly reduced in colon tumors posses-
sing low ZBRK1 transcripts. Thus, our results provide first evidence that ataxin-2 acts as a co-regulator of
ZBRK1 activating its own transcription, thereby representing the first identified ZBRK1 co-activator.
INTRODUCTION
Kru¨ppel-associated box (KRAB)-containing zinc-finger
repressor proteins represent the largest single family of tran-
scriptional regulators accounting for approximately one-third
of the different zinc-finger proteins present in the human
genome. Members of this family are involved in the tran-
scriptional repression of RNA polymerase I, II and III pro-
moters, as well as binding and splicing of RNA, resulting
in crucial functions regarding the maintenance of the
nucleolus, cell differentiation and proliferation and
apoptosis. However, for most members, the cellular function
and the underlying molecular mechanisms remain elusive
(1–3).
The zinc-finger protein 350 (ZNF350), also known as
BRCA1-interacting protein with a KRAB domain 1
(ZBRK1), was initially isolated in a yeast two-hybrid (Y2H)
screen carried out to identify proteins associated with the
breast-cancer-associated protein 1 (BRCA1) (4). ZBRK1 is a
nuclear protein with a molecular mass of 60 kDa that is ubi-
quitously expressed. From structural scrutiny, ZBRK1 com-
prises a highly conserved KRAB domain at the N-terminal
region consisting of two KRAB boxes, KRAB A and KRAB
B, which act generally as a transcriptional repressor domain
through association with co-repressor proteins (3). The
KRAB A box plays a key role in repression mediated by
binding to co-repressors, enhanced by KRAB B through yet
unknown mechanisms (5). Further, ZBRK1 encompasses
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eight consecutive Kru¨ppel-type C2H2 zinc-finger motifs in the
central region, which are responsible for DNA binding, and
the BRCA1-binding domain, termed CTRD, in the C-terminal
region, which serves as a protein–protein interaction surface
controlling ZBRK1-directed transcriptional regulation (6,7).
As to ZBRK1 function, a link to the cellular DNA damage
repair response has been provided by demonstrating that
ZBRK1 binds to the DNA recognition motif
GGGnnnCAGnnnTTT within intron 3 of the DNA
damage-responsive GADD45 gene (growth arrest and DNA
damage gene 45), thereby repressing transcription in a
BRCA1-dependent manner (8). Upon treatment of mammalian
cells with ultraviolet light or DNA-damaging agents such as
methyl methanesulfonate, ZBRK1 is rapidly degraded
through the ubiquitin–proteasome pathway and consequently
transcription of the GADD45 gene is induced. Besides,
ZBRK1 overexpression caused a decrease in both GADD45
transcripts and protein (8). Since the ZBRK1 DNA recognition
motif has been found in several BRCA1-targeted genes, a
common function of ZBRK1 in response to DNA damage
has been proposed (4).
In addition to this, ZBRK1 is implicated in the tumorigen-
esis of several human cancers. A repressor complex consisting
of ZBRK1, BRCA1 and CtIP (CtBP-interacting protein) has
been identified on the angiopoietin-1 promoter bound
through the ZBRK1 DNA recognition motif (9). Depleting
this complex paralleled with increased angiopoetin-1
expression accelerating mammary tumor growth due to promi-
nent vasculature formation. Moreover, alterations in ZBRK1
gene expression occur quite frequently in breast and colon car-
cinomas, with a tendency to ZBRK1 under-representation in
both (10,11). Low ZBRK1 transcripts have been also discov-
ered in cervical tumor cells (12). Interestingly, increased
ZBRK1 levels inhibited malignant growth, invasion and
metastasis in cervical cancer cells, indicating that ZBRK1
acts as metastatic suppressor. Elevated ZBRK1 levels resulted
in a significant upregulation of 23 genes, for example, ZNF467
(zinc-finger protein 467), VIM (vimentin), SH3GLB2
(SH3-domain GRB2-like endophilin B2) or NCAM1 (neural
cell adhesion molecule 1), which function in cellular move-
ment, gene expression as well as cellular growth and prolifer-
ation. These observations propose that ZBRK1 does not solely
function as a transcriptional repressor and suggest the exist-
ence of potential, yet unknown, co-activators (12).
In this study, we report an interaction between ZBRK1 and
the SCA2 gene product ataxin-2 (ATXN2), which is impli-
cated in the polyglutamine disorder spinocerebellar ataxia
type 2 (SCA2), and has been linked to functions in cellular
RNA metabolism and endocytotic processes (13–17). More-
over, we provide evidence that a complex comprising
ZBRK1 and ATXN2 is regulating SCA2 gene transcription.
ZBRK1 overexpression led to an increase in ATXN2 levels,
whereas lowering ZBRK1 levels resulted in reduced levels.
Finally, the application of an intrabody with interfering prop-
erties for this interaction further corroborated that a complex
comprising ZBRK1 and ATXN2 is regulating SCA2 gene tran-
scription. A bioinformatic analysis predicted ZBRK1-binding
sites (ZBSs) within the SCA2 promoter, which were
experimentally validated by chromatin-immunoprecipitation
(ChIP) experiments and promoter analyses. Of note, we
demonstrate that in colon tumors SCA2 gene transcription is
significantly reduced and is correlated to low ZBRK1 tran-
scripts. Taking all results into consideration, this is the first
report linking ATXN2 to transcriptional regulation by demon-
strating that ATXN2 functions as a co-regulator of ZBRK1
activating its own transcription.
RESULTS
The KRAB-containing zinc-finger transcriptional
regulator ZBRK1 interacts with ATXN2
Over the last years, evidence has been provided that ATXN2
functions in cellular RNA metabolism and endocytotic pro-
cesses (13–17). In order to gain further insights into its cellu-
lar functions, we carried out a Y2H screen with the LSm
domain of ATXN2 as bait protein using as prey a human
fetal brain library (Clontech). In this screen, nine yeast
clones were initially isolated from 2 × 105 transformants.
From these, only two clones were confirmed as positive prey
clones by independent Y2H experiments and sequencing
analysis, of which one encodes for part of the C-terminal
region of the KRAB-containing zinc-finger transcriptional reg-
ulator ZBRK1 (Fig. 1A, left panel). Subsequently, we per-
formed further Y2H analyses using bait plasmids encoding
different ATXN2 regions as illustrated (Fig. 1A, right panel)
and the isolated prey plasmid encoding the fusion protein
AD-ZBRK1234 – 532. This analysis revealed that the activity
of reporter genes of yeast cells expressing the fusion proteins
LexA-ATXN2(Q22)1 – 396, representing the N-terminal region
of ATXN2 comprising part of the LSm domain, and
AD-ZBRK1234 – 532 is stronger compared with yeast cells
expressing the fusion proteins LexA-ATXN2254 – 475 and
AD-ZBRK1234 – 532 (Fig. 1B, left and middle panel). To
verify specificity of this interaction, we included two other
glutamine-rich proteins, huntingtin (HDQ25) and ataxin-3
(ATXN3), as unrelated bait proteins in this study. No reporter
gene activity was observed in yeast cells expressing
LexA-HDQ25 and AD-ZBRK1234 – 532 or LexA-ATXN3 and
AD-ZBRK1234 – 532, respectively (Fig. 1B, right panel), indi-
cating that the observed interaction between the C-terminal
region of ZBRK1 and ATXN2 is specific in the Y2H system.
Next, we investigated whether this interaction occurs in
mammalian cells as well. One obstacle here is the relatively
low endogenous ZBRK1 level in a high number of human
cell lines according to the human protein atlas (http://www.
proteinatlas.org). Therefore, we first carried out
co-immunoprecipitation experiments by transfecting cells
with the expression plasmid pTL-FLAG-ZBRK1 or
pTL-FLAG as a control. Cells were lyzed and processed as
described in Materials and Methods. As shown in Figure 1C,
FLAG-tagged ZBRK1 was precipitated with an antibody
directed against ATXN2; no protein was precipitated from
the control lysate. By confocal microscopy, we were able to
detect a nuclear localization of transiently overexpressed
ZBRK1 and endogenous ATXN2 next to its cytoplasmic
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Figure 1. The transcriptional regulator ZBRK1 interacts with ATXN2. (A) Schematic illustration of ZBRK1 and ATXN2 and regions thereof used in the Y2H
system. The oblongs represent the KRAB domain and the zinc fingers within ZBRK1 (left panel) or the polyglutamine domain with 22 glutamines (polyQ), the
LSm and LSmAD domain and the PAM2 motive within ATXN2 (right panel). (B) Yeast strain L40ccua was co-transformed with the relevant bait and prey
plasmids, and transformants were selected and spotted onto selective media or membrane to analyze the activity of the reporter genes. LacZ reporter activity
was also determined by liquid b-galactosidase assay. (C) Co-immunoprecipitation experiments. Hek293T cells were transfected with plasmid
pTL-FLAG-ZBRK1 or pTL-FLAG as a control. Cell lysates were incubated with an antibody directed against ATXN2 and precipitated proteins were visualized
as indicated. (D) Confocal microscopy. HeLa and U2OS cells were transiently transfected with plasmid pTL-FLAG-ZBRK1. Sixteen hours post-transfection
cells were fixed and stained with specific antibodies for ATXN2 and FLAG-tag. (E) Detection of endogenous ZBRK1 and ATXN2 in HeLa nuclei extract
using an antibody against ZBRK1 and two different antibodies directed against ATXN2 (upper panel). Co-immunoprecipitation of ATXN2 from HeLa
nuclei extract with an antibody directed against ZBRK1. Detection with ATXN2 antibody (BD Biosciences) (lower panel).
106 Human Molecular Genetics, 2011, Vol. 20, No. 1
localization in HeLa and U2OS cells, which have been utilized
in functional ZBRK1 characterization studies (4,8,12)
(Fig. 1D). Therefore, we carried out additional co-immuno-
precipitation experiments using commercially available HeLa
nuclei extracts. Endogenous ATXN2 was precipitated from
nuclei extracts using an antibody directed against endogenous
ZBRK1 (Fig. 1E). Thus, these experiments demonstrate that an
association between ZBRK1 and ATXN2 takes place in mam-
malian cells.
SCA2 gene transcription is coordinated by a ZBRK1/
ATXN2 complex
Some cells transiently overexpressing ZBRK1 seem to exhibit
a higher cellular ATXN2 immunoreactivity compared with
non-transfected cells (Fig. 1D). We therefore transfected
Hek293T cells with plasmid pCMV-MYC-ZBRK1 or control
vector pCMV-MYC to determine the protein levels of
ATXN2 in the presence of elevated ZBRK1 levels. Cells
were lyzed 48 h post-transfection and lysates were subjected
to sodium dodecyl sulphate–polyacrylamide gel electrophor-
esis (SDS–PAGE) and western blotting. As shown in
Figure 2A, cell lysates derived from cells transiently overex-
pressing ZBRK1 exhibited an elevated ATXN2 level in com-
parison to control lysates. We also investigated the effect of
ZBRK1 depletion on the SCA2 gene product by RNA interfer-
ence experiments as well. For these, Hek293T cells were
transfected with siRNA molecules specific for ZBRK1 as
well as unspecific siRNA as a control. As analyzed by
reverse transcription–quantitative real-time PCR (RT–
qPCR), treatment of cells with ZBRK1-specific siRNA
resulted in a ZBRK1 knockdown efficiency of 60–65%
(data not shown). As expected, the endogenous ATXN2
level in lysates of ZBRK1-depleted cells was reduced in com-
parison to respective control cell lysates (Fig. 2B). Finally, we
generated and applied an intrabody with interfering properties
for this interaction following an approach as described in
Materials and Methods. Expression of this intrabody in mam-
malian cells and subsequent immunoprecipitation experiments
revealed that this intrabody precipitated endogenous ZBRK1,
indicating specificity (Fig. 2C, upper panel). Interestingly,
we observed that the expression of this intrabody resulted in
lowered ATXN2 levels than expression of a control intrabody
(Fig. 2C, lower panel). Thus, our results suggest that a
complex comprising ZBRK1 and ATXN2 regulates SCA2
gene transcription and consequently ATXN2 levels.
The SCA2 promoter comprises ZBRK1-binding motifs
In order to corroborate the assumption that ZBRK1 and ATXN2
are coordinately regulating SCA2 gene transcription, we sub-
sequently performed a SCA2 promoter analysis exploiting the
annotated ZBRK1-binding motif GGGnnnCAGnnnTTT. This
motif was originally identified by sampling a random pool of
double-stranded oligonucleotides with recombinant ZBRK1
lacking the C-terminal region that is important for the oligomer-
ization of ZBRK1 (4). Notably, the search for occurrences of the
International Union of Pure and Applied Chemistry (IUPAC)
string GGGnnnCAGnnnTTT or its reverse complement allowing
up to three mismatches in the outer two nucleotide triplets
resulted in the identification of seven putative ZBSs within the
analyzed SCA2 sequence region (Fig. 3A, left panel). To validate
these experimentally, we performed ChIP experiments focussing
on four predicted sites: ZBS1 and ZBS2, which are located near
the transcriptional start site (TSS) and partly overlap; ZBS3,
which is located in a non-conserved region of the SCA2 promoter,
as well as ZBS4, which is located in the coding sequence of exon
1 of the SCA2 gene. Cells were crosslinked with formaldehyde,
Figure 2. Expression of the SCA2 gene product is regulated by a ZBRK1/
ATXN2 complex. (A) ZBRK1 overexpression experiments. Hek293T cells
were transfected with pCMV-MYC-ZBRK1 or control vector and lyzed 48 h
post-transfection. Proteins were visualized with antibodies as indicated.
Coomassie-stained gels served as loading controls. (B) Knockdown exper-
iments. Hek293T cells were transfected with unspecific or ZBRK1-specific
siRNA or left untreated. Then, cells were incubated for 96 h, lyzed and
protein levels were analyzed by immunoblotting. Coomassie-stained gels
served as loading controls. (C) Immunoprecipitation experiments. Hek293T
expressing FLAG-ZBRK1 intrabody or control cells were lyzed and incubated
with an antibody directed against the FLAG-tag. Precipitated ZBRK1 was
visualized by a ZBRK1 antibody (upper panel). Interference experiments.
Hek293T cells were transfected with the respective intrabody plasmid or a
control intrabody plasmid. Sixteen hours post-transfection, lysates were pre-
pared and subjected to immunoblotting analysis. As the internal loading
control, TIA-1 levels were used (lower panel). All experiments have been per-
formed at least two times obtaining the same results.
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lyzed and nuclei were isolated. After sonification of genomic
DNA, samples were incubated with an antibody against
ZBRK1 or ATXN2. Precipitated DNA fragments were analyzed
by RT–qPCR using primers encompassing a 120 bp fragment
around the predicted ZBRK1-binding motifs. Using an antibody
directed against ZBRK1, we were able to precipitate and highly
enrich DNA fragments containing the ZBRK1-binding motif
ZBS4 (Fig. 3A, right panel). Moreover, DNA fragments contain-
ing ZBS3 were precipitated; however, enrichment was weak. No
enrichment was observed for ZBRK1-binding motifs ZBS1 and
ZBS2. Nonetheless, all four ZBRK1-binding motifs were preci-
pitated and significantly enriched with an antibody directed
against ATXN2 (Fig. 3A, right panel). Thus, we concluded that
ZBRK1 and ATXN2 form a complex bound to the ZBSs
within the SCA2 promoter regulating SCA2 gene transcription.
To sustain this finding, we carried out additional promoter
studies. For these, we generated Firefly expression plasmids
pGL3-ATXN2 containing SCA2 promoter sequences com-
prising the ZBS1–3 and pGL3-ATXN2-Exon1 containing
SCA2 promoter sequences comprising all predicted ZBSs
Figure 3. ZBRK1 binds the SCA2 promoter through internal ZBSs. (A) Illustration of the genomic location of the SCA2 promoter relative to Ensembl 46/
NCBI36. PHASTCONS 44-way vertebrate sequence conservation was imported from UCSC browser (35), with conserved regions shown in red. Regions of
the analyzed SCA2 sequence region are shown in green, exon 1 of the SCA2 gene is shown in blue and the UTR in turquoise. CpG island (yellow) location
was defined with method of Gardiner-Garden and Frommer (36). Putative ZBSs are depicted in turquoise. Binding sites chosen for ChIP experiments were
named ZBS1–4, uncharacterized were named U1–3. Genomic coordinates are relative to Ensembl 46/NCBI36 (upper left panel). Putative ZBSs within the ana-
lyzed SCA2 sequence region. Capitalized bases in the sequence correspond to conserved positions in the ZBRK1 SELEX motif. Positions are marked in bold if
the respective nucleotide occurs at least once in this position in a sequence from the SELEX set (lower left panel). ChIP experiments. MCF-7 cells were lyzed
and chromatin DNA was immunoprecipitated with antibodies directed against ZBRK1 or ATXN2, validated by qPCR using primers encompassing the predicted
ZBSs and normalized to control DNA. The chromosomal region of IL-4 (chr5:132037145–132037263) served as a negative control. Bars indicate the standard
error of the mean (right panel). (B) Schematic illustration of the SCA2 reporter constructs pGL3-ATXN2 (chr12:110521888-110522915) and pGL3-ATXN2-
Exon1 (chr12:110521729-110522910) (upper left panel). Promotor analysis. Hek293T cells were transfected with plasmids pGL3-ATXN2 or pGL3-ATXN2-
Exon1, plasmid pRL-TK-Renilla and plasmid pCMV-HA-ZBRK1 or empty vector or pCMV-MYC-ATXN2-Q22 or empty vector, respectively. Twenty-four
hours post-transfection, cells were lyzed, the expression of Firefly and Renilla luciferase were measured and their ratios were set in relation to pGL3basic.
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(Fig. 3B, upper left panel). Hek293T cells were transiently
transfected with plasmids pGL3-ATXN2 or pGL3-ATXN2-
Exon1, plasmid pRL-TK-Renilla encoding Renilla luciferase
and plasmid pCMV-HA-ZBRK1 or empty vector, respect-
ively, as indicated. After transfection, cells were lyzed and
expression of Firefly and Renilla luciferase was measured
and their ratios were set in relation to pGL3basic. As
shown in Figure 3B, ZBRK1 overexpression led to an
increase in SCA2 promoter activity that was stronger in
case all ZBSs were present (left panel). On the other hand,
the same set of experiments was performed with cells transi-
ently overexpressing ATXN2. As observed for ZBRK1, elev-
ated ATXN2 levels resulted in enhanced SCA2 promoter
activity as well (Fig. 3B, right panel). Taking all these
results into consideration, we concluded that ZBRK1 acts
as an activator on SCA2 gene transcription and that
ATXN2 represents a co-regulator, most probably a
co-activator, regulating its transcription through complex for-
mation with ZBRK1.
ATXN2 transcripts are reduced in colon cancer patient
material with low ZBRK1 transcripts
Since low ZBRK1 expression has been observed in diverse
human carcinomas, e.g. in 50% of hepatocellular carcinomas
and 37.5% of colorectal cancers (10–12), we finally set out
to investigate whether the observed correlation between
ZBRK1 and ATXN2 in vitro is also reflected at the transcrip-
tional level in cancer tissues. Samples of matching normal and
tumor tissues of five colon cancer patients were collected,
macrodissected and transcriptional levels of ZBRK1 and
SCA2 gene were determined by quantitative RT–qPCR. As
expected, all colon tumor tissues showed a decrease in
ZBRK1 transcripts in comparison to their normal counterparts
(Fig. 4). In addition, reduced SCA2 gene transcripts were
detected in all tumor tissues compared with their normal
counterparts as well. Taken together, these results draw a par-
allel with the observations made in our cell culture exper-
iments demonstrating a correlation between ZBRK1 and
SCA2 gene transcription further strengthening the assumption
that a complex comprising ZBRK1 and ATXN2 regulates
SCA2 gene transcription.
DISCUSSION
In this study, we report for the first time on an interaction
between the transcriptional regulator ZBRK1 and ATXN2.
This interaction occurs with the C-terminal region of
ZBRK1 that mainly consist of the BRCA1-binding
domain, termed CTRD. Of note, this domain has been
shown to be responsible for tetrameric oligomerization of
ZBRK1 assembling on ZBRK1 DNA consensus motifs and
thus facilitating ZBRK1-directed transcriptional repression
(7). Additionally, evidence has been provided that the regu-
latory potential of ZBRK1 on certain target genes may also
derive from its recruitment via CTRD-dependent protein–
protein interactions rather than protein-DNA interactions
(7); for example, binding of the tumor suppressor BRCA1
to CTRD is responsible for BRCA1-dependent transcrip-
tional repression of several DNA damage-response genes
(4). However, a role for additional co-regulators of the
CTRD domain has been proposed mainly based on the
observation that binding of BRCA1 is necessary, however
not sufficient for ZBRK1 repression function (7). In this
regard, the transcription factors serum response factor
(SRF) and activating trancription factor 1 (ATF-1) were
found to bind to the CTRD domain in the Y2H system,
however, further investigations have not yet been reported
(7). Based on our finding, we propose that ATXN2 also
acts through its binding to the CTRD, representing a novel
co-regulator of ZBRK1. We discovered potential ZBSs in
the SCA2 promoter and experimentally verified them by
ChIP experiments further demonstrating that ATXN2 is
found in a complex with ZBRK1 bound to the promoter.
We suggest that ATXN2 acts through its interaction with
sequence-specific DNA binding transcription factors as it
has been described for BRCA1 that is involved in both acti-
vation and repression of gene transcription through its direct
interaction with several DNA-binding transcription factors
(6,18–21). To this point, ATXN2 function was previously
linked to roles in the cellular RNA metabolism and endocy-
totic processes (13–17). However, this is the first report pro-
viding evidence that ATXN2 is implicated in transcriptional
regulation.
Furthermore, we demonstrate that a complex comprising
ZBRK1 and ATXN2 is activating the transcription of the
SCA2 gene itself, thus suggesting that ATXN2 functions as
co-activator of ZBRK1. Transient ZBRK1 overexpression
resulted in increased ATXN2 protein levels, whereas
ZBRK1 depletion or interaction interference resulted in
reduced ATXN2 levels. Moreover, increased SCA2 promoter
activity was found in the case of elevated ZBRK1 or
ATXN2 levels. Although ZBRK1 and other KRAB-containing
zinc-finger proteins are thought to function mainly as tran-
scriptional repressors, a dual function in gene repression and
activation has been reported recently. Global expression profil-
ing of HeLa or U2OS cells stably overexpressing ZBRK1
clearly demonstrated the transcriptional activation of numer-
ous genes, however, by yet unknown mechanisms and
co-activators (12). Moreover, depletion of the KRAB-
containing zinc-finger protein ZNF263 showed that this tran-
scriptional regulator has activating as well as repressing
effects on target gene transcription (22).
Figure 4. SCA2 gene transcription is reduced and correlates with low ZBRK1
transcripts in colon cancer patient tissue. RT–qPCR analysis. Isolated RNA
from matching normal and tumor tissues of five colon cancer patients were
analyzed by RT–qPCR. Bars indicate the standard error of the mean.
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Alterations in ZBRK1 gene expression have been frequently
observed in human carcinomas, with a tendency to ZBRK1
under-representation (10–12). We observed that low ZBRK1
transcripts in colon cancer tissues correlate with low SCA2
gene transcripts when compared with matching control colon
tissue. In this regard, low ATXN2 levels have been linked to
poor outcome of human neuroblastoma cells, a highly hetero-
geneous tumor of young children, whereas enforced
expression of ATXN2 levels sensitizes neuroblastoma cells
for apoptosis (23). Hence, it is tempting to speculate that the
deregulation of ATXN2 is due to impairment in the ZBRK1/
ATXN2 complex as it is for colorectal cancers, where we
have selected advanced colorectal cancer cases with a meta-
static disease.
As illustrated in Figure 5, deciphering the role of
ATXN2 in transcriptional regulation and its potential func-
tion as the co-activator of ZBRK1, identifying additional
components of the ATXN2/ZBRK1 complex and how
alterations of the ATXN2/ZBRK1 complex affect target
genes will be an interesting task to address in the future
perspective.
Besides ATXN2’s potential impact in tumorigenesis, one
should keep in mind that ATXN2 has been linked to the
neurodegenerative disorder SCA2, which is characterized
by expansion of the trinucleotide repeat CAG in the
SCA2 gene encoding an enlarged polyglutamine region
within ATXN2 (24–26). Remarkably, evidence has been
provided that the accumulation of disease ATXN2 is contri-
buting to cellular dysfunction, and finally SCA2 pathogen-
esis (27). Although tumorigenesis and neurodegeneration
are different pathologies, common factors and overlapping
pathways were identified over the last years, interestingly,
often with complementary relationships. In this perspective,
it will be of interest to study the effect of an expanded glu-
tamine region within ATXN2 in regard to the interaction
with ZBRK1 and the resulting consequences. Notably,
first Y2H results indicate that the interaction between
ATXN2 and ZBRK1 is affected in the disease state. Deci-
phering the resulting consequences of an altered ATXN2/
ZBRK1 complex formation and how this contributes to
SCA2 pathogenesis will be tremendously helpful in defining




The Y2H bait plasmids used and the mammalian expression
plasmid pCMV-MYC-ATXN2-Q22 were described earlier
(14,16–17). To generate the mammalian expression plasmid
pCMV-MYC-ZBRK1, the open-reading frame of the ZBRK1
gene was amplified via PCR using plasmid pOTB7-ZBRK1
(RZPD, IRAUp969A0148D) as the template DNA and the oli-
gonucleotide pair ZBRK1-s-SalI and ZBRK1-as-NotI. The
resulting DNA fragment was treated with the restriction endo-
nucleases SalI/NotI and subcloned into the SalI/NotI sites of
the vector pCMV-MYC. Plasmids pCMV-HA-ZBRK1 and
pTL-FLAG-ZBRK1 were created by subcloning the SalI/
NotI DNA fragment from pCMV-MYC-ZBRK1 into the
SalI/NotI sites of the vector pCMV-HA or the XhoI/NotI
sites of the vector pTL-FLAG, respectively.
The SCA2 promoter constructs, pGL3-ATXN2 and pGL3-
ATXN2-Exon1, were amplified by PCR using genomic
SW480 DNA and primer pair pGL3-ATXN2-FW and
pGL3-ATXN2-RV or pGL3-ATXN2- Exon1-FW and pGL3-
ATXN2-Exon1-RV, respectively. Subsequently, the amplified
promoter regions were subcloned into the pGL3basic vector
by Gateway BP clonase (Invitrogen) as recommended by the
manufacturer. All DNA fragments were validated by sequen-
cing. Primers are listed in Table 1. Underlined sequences rep-
resent restriction sites.
Y2H analysis
Y2H analyses were performed as described previously using the
yeast strain L40ccua (16,17,28). After transformation of the
respective bait and prey plasmids, the yeast transformants
were isolated and single clones were spotted onto solid selective
SD media lacking tryptophan, leucine (SDII) or SD media
lacking tryptophan, leucine, uracil and histidine (SDIV) as
well as on nylon membrane (MSI). After 3–5 days, growth of
yeast on selective media was monitored. To analyze the activity
of the LacZ reporter gene, the membrane was incubated in liquid
nitrogen and incubated on Whatman paper that has been
saturated with X-Gal buffer [phosphate buffer pH 7.0,
0.15% X-Gal (bromo-chloro-indolyl-galactopyranoside),
10 mM DTT] for 6–8 h at 378C. The liquid b-galactosidase
assay was performed as described (16).
Cell cultivation and transfection
MCF-7, U2OS, HeLa and Hek293T cells were cultivated in
Dulbecco’s modified Eagle’s medium (Invitrogen) sup-
plemented with 10% heat-inactivated fetal calf serum (Bio-
chrom) and 1% penicillin/G-streptomycin (Biochrom) at
378C and 5% CO2. For overexpression studies, cells were
plated on adequate plates and grown until a confluence of
50–70%. Transfections were performed with polyethyleni-
mine (PEI; Polysciences).
Figure 5. Schematic model for SCA2 transcriptional regulation by ZBRK1/
ATXN2 complex.
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Co-immunoprecipitation experiments
Co-immunoprecipitation experiments were performed using
Hek293T cells or HeLa nuclei (Santa Cruz). Hek293T cells
were grown in 15 mm plates and transfected with 42 ml of
PEI and 25 mg of vectors pTL-FLAG-ZBRK1 or pTL-FLAG
as a control. Forty-eight hours after transfection, cells were
washed in 1× PBS (phosphate-buffered saline pH 7.4), har-
vested and lyzed in lysis buffer [1× PBS, 5 mM EDTA (ethy-
lenediaminetetraacetic acid), 0.5% Triton X-100, 2.5%
protease inhibitor (complete tablets, Roche), 25 U/ml of ben-
zonase (Merck)] for 45 min at 48C. Afterwards, 0.75 mg of
mouse-ATXN2 antibody (BD Biosciences) were added to
1 mg of each cell lysate and incubated for 90 min on a rotating
wheel at 48C. Subsequently, 20.1 × 105 beads of sheep
anti-mouse IgG Dynabeads M-280 (Invitrogen) were added
and lysates were further incubated for 3 h. For experiments
using HeLa nuclei, 1 mg of mouse-ZBRK1 antibody (gift
from Wen-Hwa Lee, University of California, Irvine, USA)
was added to 250 mg of nuclei extract. After incubation of
samples for 3 h on a rotating wheel at 48C, 10.05 × 105
beads of sheep anti-mouse IgG Dynabeads M-280 (Invitrogen)
were added and the samples were incubated for an additional
hour at 48C. Dynabeads were pulled down magnetically and
washed three times with 3% BSA (bovine serum albumin)/
PBS and three times with PBS. To separate proteins from
magnetic beads, 5× SDS sample buffer was added to
samples and incubated for 5 min at 958C. Proteins were separ-
ated by 7.5% SDS–PAGE and transferred to nitrocellulose
membrane (Protran, Perkin Elmer) using a Perfect Blue
semidry electroblotter (PeqLAB). Membranes were incubated
in blocking solution (5% milk in 1× PBS) for 1 h at room
temperature (RT), washed with PBS and incubated overnight
with the respective primary antibody at 48C [1:100,
rabbit-ZBRK1 antibody (ATLAS antibodies); 1:1000,
rabbit-ZBRK1 antibody (Abcam); 1:1000 mouse-ZBRK1 anti-
body (gift from Wen-Hwa Lee); 1:1000 mouse-ATXN2 anti-
body (BD Biosciences); 1:500, rabbit-ATXN2 antibody
(Bethyl); 1:1000, rabbit-MYC antibody (Sigma-Aldrich);
1:5000, rabbit-FLAG antibody (Sigma-Aldrich); 1:5000,
mouse-FLAG antibody (Sigma-Aldrich)]. Next, membranes
were washed and incubated with the corresponding secondary
peroxidase-coupled or alkaline phosphatase-coupled antibody
[mouse-POD-conjugate or rabbit-POD-conjugate, 1:10 000
(Sigma-Aldrich); goat-AP-conjugate and mouse-AP-conju-
gate, 1:10 000 (Jackson ImmunoResearch Laboratories)] for
2 h at RT. To visualize proteins, membranes were treated
with Western Lightning luminol reagent (PerkinElmer) or
SuperSignal West Femto (Thermo Scientific) and exposed to
Amersham Hyperfilm ECL (Kodak). Membranes incubated
with secondary alkaline phosphatase-coupled antibody were
treated with Western Bluew (Promega).
Bioinformatic analysis
A search for ZBRK1-binding motifs within the SCA2 promo-
ter was performed using the SELEX-derived ZBRK1-binding
motif described by Zheng et al. (4). For this, a scan for
matches to the IUPAC string GGGnnnCAGnnnTTT was per-
formed allowing for up to three mismatches restricted to the
outer nucleotide triplets. The genomic sequence around the
TSS of the SCA2 gene as annotated in Ensembl v. 46, compris-
ing 500 bp upstream and 300 bp downstream of the TSS, was
extracted (29).
ChIP experiments
ChIP experiments were carried out as described previously
(30). MCF-7 cells were lyzed, nuclei were isolated and
genomic DNA was sonificated to an average size of 400–
800 bp. Shared samples were incubated overnight with
10 mg of the respective antibody [rabbit-ZBRK1 antibody
(Abcam), mouse-ATXN2 antibody (BD Biosciences)] and
precipitated with Protein A Dynabeads (Invitrogen). Enrich-
ment of potential ZBRK1-binding motifs within the analyzed
SCA2 sequence region was analyzed with RT–qPCR. Primers
used in these experiments are listed in Table 1.
Quantitative real-time PCR
qPCR and RT–qPCR were applied to monitor genomic frag-
ments or mRNA levels in colorectal cancers tissues, respect-
ively. For the cDNA synthesis of a normal tumor mRNA,
30–300 ng of total RNA was reverse-transcribed with
oligo-dT primers and SuperScriptII reverse transcriptase
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(Invitrogen) in a 20 ml reaction. qPCRs were performed in tri-
plicates using Absolute SYBR Green PCR Master Mix
(Applied Biosystems) in a 10 ml reaction volume on
a PRISM 7900HT sequence detection system (Applied Bio-
systems). The predicted threshold cycle (Ct) values and the
amplification plot were obtained with the Sequence Detection
software (SDS 2.1, Applied Biosystems). The housekeeping
gene HPRT1 (Hypoxanthine-guanine phosphoribosyltransfer-
ase) was used as the internal control, since it represents the
best single reference gene for the standardization of gene
expression measurements in cancer research (31).
Fold change was calculated with the DDCt method (User
Bulletin #2, Applied Biosystems). Primers used are listed in
Table 1.
Luciferase promoter activity assay
For promoter activity assays, Hek293T cells were plated in
96-well plates and transfected with 3 ml of PEI and 50 ng of
plasmid pGL3-ATXN2 or pGL3-ATXN2-Exon1, respectively,
5 ng of plasmid pRL-TK-Renilla and 100 ng of plasmids
pCMV-HA-ZBRK1 or pCMV-MYC-ATXN2-Q22 or control
vectors, respectively. Thirty-six hours post-transfection, cells
were lyzed in 20 ml 1× Passive Lysis Buffer (Promega) for
15 min at RT and lysates were transferred to 96-well clear
bottom plates. Firefly and Renilla luciferase activities were
measured using the Dual-Luciferase Reporter Assay
(Promega E1910) in a Centro LB960 luminometer (Berthold).
Afterwards, Firefly luciferase activity was normalized to
Renilla luciferase activity and ratios were set in relation to
pGL3basic.
RNA interference experiments
RNA interference experiments were performed using
Hek293T cells. For transfection, 30 000 cells were plated in
a 12-well plate and transfected with HiPerfect (Qiagen) and
300 ng of the following small interfering RNA (siRNA) mol-
ecules: si-ZBRK1 (On Target smart pool human ZNF350,
Dharmacon), si-ATXN2 (On Target smart pool human
SCA2, Dharmacon) or si-NS (On Target plus, non-targeting
siRNA, Dharmacon) as a control. Ninety-six hours post-
transfection, cells were either lyzed in lysis buffer [1× PBS,
5 mM EDTA, 0.5% Triton X-100, 2.5% protease inhibitor
(complete tablets, Roche), 25 U/ml of benzonase (Merck)]
for 45 min at 48C or harvested for total RNA extraction
using RNAeasy mini kit (Qiagen).
Confocal microscopy
U2OS and HeLa cells plated on glass slides were transfected
with 3.3 ml PEI and 1 mg DNA of the corresponding plasmids
and incubated for 16 h to allow transient expression of pro-
teins. Cells were fixed with ice-cold methanol for at least
45 min and treated with 3% BSA. Subsequently, cells
were incubated with primary antibodies (ATXN2, 1:200;
BD Biosciences), FLAG (mouse and rabbit, 1:500;
Sigma-Aldrich) for 1 h at RT, washed and incubated with
respective secondary antibodies (mouse-AlexaFluor488,
1:500; Molecular Probes), rabbit-AlexaFluor568 (1:500;
Molecular Probes). Afterwards, samples were mounted with
Fluoromount-G (SouthernBiotech) and analyzed by confocal
microscopy using an LSM700 (Zeiss).
Generation of interfering intrabodies
The generation of intrabodies comprises an in vitro and an in
vivo screening step applying phage display and a modified
Y2H screen, respectively (Konthur et al., manuscript in prep-
aration). Briefly, potentially binding single-chain Fragment
variables (scFv) were enriched in vitro from the human single-
fold scFv library I (32). As selection target, the ZBRK1-CT
was recombinantly expressed as in vivo biotinylated protein
in Escherichia coli using the vector pRSET-BH6, where it
was cloned via SalI/NotI as described above. Panning was
carried out in solution applying a semi-automated selection
protocol using magnetic beads in a magnetic particle processor
as described before (33,34). Next, the enriched pools of scFvs
were PCR amplified from the individual selection rounds
using primers VH-tom-NcoI-f and VL-tom-NotI-rev, digested
with the restriction endonucleases NcoI/NotI and subcloned
into the NcoI/NotI restriction sites of the yeast expression
vector pIB-NLS. For the in vivo-selection screening of intra-
bodies, the yeast strain L40ccuA/ade was generated and
used. In brief, strain L40ccuA/ade expressing fusion proteins
LexA-ATXN2-NT221 – 396 and AD-ZBRK1-CT was trans-
formed with an intrabody library selected for ZBRK1-CT or
with an unselected intrabody library as a control. For each
library, 1152 transformants were isolated and spotted onto
selective SDIII and SDV media plates. Yeast clones that did
not show growth on SDV medium were indicative of carrying
an intrabody with interfering properties for the ATXN2/
ZBRK1 interaction. Subsequently, intrabody plasmids were
isolated from the respective yeast clones and re-transformed
for validation. Finally, plasmid-DNA derived from positive
validated yeast clones was used as the template for
PCR using primers 5’scFv-HindIII-pFLAG und 3’scFv-
pFLAG. scFv amplicons were digested with restriction endo-
nucleases HindIII/NotI and subcloned into the restriction
sites HindIII/NotI of the mammalian expression vector
pFlagCMV5a-ccdB.
Intrabody interference
For intrabody expression in mammalian cells, transfection was
performed with 2 mg of the respective pFlagCMV5a
expression construct. Forty-eight hours post-transfection,
cells were lyzed in lysis buffer (50 mM Tris–HCl pH 8.8,
100 mM NaCl, 5 mM MgCl2, 0.5% NP-40, 1 mM EDTA). Pro-
teins were separated by 4–12% Bis–Tris–Gel (NuPAGE
Novex, Invitrogen) according to the manufacturer’s instruc-
tions and electrophoretically transferred to nitrocellulose
membrane (Hybond ECL, GE Healthcare). Afterwards, mem-
branes were incubated in 1% Tween, 2% Blocking Grade
Blocker solution (BioRad) for at least 1 h at RT, washed
three times with PBS/0.1% Tween followed by incubation
with the first antibody overnight at 48C as described above.
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Tissue samples
Human tissues (ethics committee application number, 20-066)
obtained during surgery were immediately snap-frozen in
liquid nitrogen and stored at 2808C until they were processed.
Patients selected had advanced colorectal cancers and were
classified pT2N0M1 or higher. From each patient, normal
and matching tumor samples were collected. Cryosections
(3 mm thick) were prepared and stained with hematoxylin
and eosin to evaluate tumor cell content. Dissections were per-
formed under the microscope to achieve a tumor cell content
of more than 80%. RNA isolation was performed using the
AllPrep DNA/RNA/Protein Mini Kit (Qiagen), according to
the manufacturer’s instructions, quantified and analyzed with
the Bioanalyzer (Agilent).
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